犬模型经动脉选择性灌注载Delta-24间充质干细胞的安全性与可行性
本研究在10只正常犬中经股动脉途径,用微导管向颈内动脉或大脑后动脉P1段灌注载Delta-24-RGD的人骨髓间充质干细胞,评估栓塞性卒中等毒性。前循环递增剂量至1×10^8细胞/10 mL未见卒中,后循环插管2只出现缺血及出血性卒中,支持开展临床试验。
要点
- 犬前循环经动脉灌注hMSC-D24至1×10^8细胞/10 mL未见卒中。
- 后循环P1段插管2只犬出现缺血及出血性卒中。
- 阳性对照颗粒注射2只犬均检出卒中,验证检测敏感性。
核心结论
- 经动脉选择性灌注hMSC-D24在犬前循环至少可安全达到1×10^8细胞/10 mL(10^7细胞/mL)的剂量。
- 结果支持开展经动脉选择性灌注hMSC-D24的临床试验。
研究设计与样本
- 在10只正常犬中经股动脉途径用市售微导管行经动脉选择性灌注,靶血管为颈内动脉(n=7)或大脑后动脉P1段(n=3)。
- 一侧半球注入递增浓度的hMSC-D24或颗粒(阳性对照),对侧灌注生理盐水(阴性对照)。
- 通过灌注后血管造影、弥散加权磁共振成像、临床检查和尸检评估毒性,尤其关注栓塞性卒中。
主要发现
- 2只注射颗粒的阳性对照犬所有检测均检出卒中。
- 6只经前循环注射hMSC-D24的犬剂量从2×10^6细胞/20 mL递增至1×10^8细胞/10 mL,均未发生卒中。
- 2只犬在后大脑动脉插管后出现缺血性和出血性卒中。
- 2只受试犬的生存实验在处死前24小时内未检测到并发症。
关键数值与推荐
- 前循环hMSC-D24递增剂量范围为2×10^6细胞/20 mL至1×10^8细胞/10 mL(即10^7细胞/mL)。
- 阳性对照颗粒注射后所有检测均检出卒中。
临床怎么用
- 提示经动脉选择性灌注hMSC-D24在前循环使用市售微导管具有可行性,可支持后续临床试验设计。
- 后循环插管与卒中事件相关,临床转化时需特别评估后循环操作风险。
局限性
- 研究为正常犬模型,非荷瘤模型,未评估对肿瘤的疗效。
- 样本量小(10只犬),生存实验仅2只、观察24小时。
- 后循环插管相关卒中的机制与可避免性未进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delta-24-RGD, an oncolytic adenovirus, shows promise against glioblastoma. To enhance virus delivery, we recently demonstrated that human bone marrow-derived mesenchymal stem cells loaded with Delta-24-RGD (hMSC-D24) can eradicate glioblastomas in mouse models. There are no studies examining the safety of endovascular selective intra-arterial (ESIA) infusions of MSC-D24 in large animals simulating human clinical situations. OBJECTIVE: To perform canine preclinical studies testing the feasibility and safety of delivering increasing doses of hMSCs-D24 via ESIA infusions. METHODS: ESIA infusions of hMSC-D24 were performed in the cerebral circulation of 10 normal canines in the target vessels (internal carotid artery [ICA]/P1) via transfemoral approach using commercially available microcatheters. Increasing concentrations of hMSC-D24 or particles (as a positive control) were injected into 1 hemisphere; saline (negative control) was infused contralaterally. Toxicity (particularly embolic stroke) was assessed on postinfusion angiography, diffusion-weighted magnetic resonance imaging, clinical exam, and necropsy. RESULTS: ESIA injections were performed in the ICA (n = 7) or P1 (n = 3). In 2 animals injected with particles (positive control), strokes were detected by all assays. Of 6 canines injected with hMSC-D24 through the anterior circulation, escalating dose from 2 × 106 cells/20 mL to 1 × 108 cells/10 mL resulted in no strokes. Two animals had ischemic and hemorrhagic strokes after posterior cerebral artery catheterization. A survival experiment of 2 subjects resulted in no complications detected for 24-h before euthanization. CONCLUSION: This novel study simulating ESIA infusion demonstrates that MSCs-D24 can be infused safely at least up to doses of 1 × 108 cells/10 mL (107 cells/ml) in the canine anterior circulation using commercially available microcatheters. These findings support a clinical trial of ESIA infusion of hMSCs-D24.
引用
- Srinivasan VM, Gumin J, Camstra KM, et al. Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model. Neurosurgery. 2020. PMID: 33231254. doi:10.1093/neuros/nyaa470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。